Syntheses, crystal structure and cytotoxicity of diamine platinum(II) complexes containing maltol
Introduction
In a series of recent reports [1], [2] we have described the chemistry and biological properties of a set of DNA targeted platinum complexes 1 (Fig. 1) in which the (1,2-diaminoethane)platinum(II) moiety is tethered to the acridine-4-carboxamide chromophore. These complexes have emerged as clear candidates for further development because they show promising activity against cisplatin resistant cell lines and most significantly a different DNA sequence specificity [3] to that of cisplatin. These compounds are of limited aqueous solubility and overcoming this deficiency is an important practical objective if these compounds are to be exploited as useful drugs. One way of doing this is to adopt the widely used approach of replacing the chloride leaving groups with chelating oxygen donors. This strategy has, for example, led to the development of the neutral compounds such carboplatin 2, oxaliplatin 3, nedaplatin 4 and the cationic complex TRK-710 5 [4]. A further suitable ligand for use as an oxygen-based chelate would be 3-hydroxy-2-methyl-4-pyrone (Maltol) 6. The maltolato anion has been shown to function as a bidentate chelate with a wide range of metal ions and the bis(maltolato)oxovanadium(IV) complex BMOV shows promise as a therapeutic agent for the treatment of type 2 diabetes mellitus [5].
As a prelude to incorporation of the maltolate anion in the acridine systems 1 we were motivated to carry out model studies with simpler diamine platinum complexes. If the maltolate anion is to be useful as the leaving group in the acridine complexes 1 it first needs to be established that: (i) the synthesis of maltolato platinum(II) complexes may be carried out in a straightforward manner, (ii) maltolato complexes are far more soluble than their dichloro analogues, and, (iii) mixed ligand platinum(II) diamine maltolato complexes are cytotoxic. There has been one report in the patent literature [6] on a cytotoxic compound formulated as [Pt(trans-1,2-diaminocyclohexane)maltolato)]OH although in this case little detail was provided on the synthesis and characterisation of the material.
With these objectives in mind we describe in this report the synthesis and spectral characterisation of the cationic complexes (1,2-diaminoethane)(maltolato)platinum(II) ([Pt(en)(ma)]+) (7) and (1R,2R-1,2-diaminocyclohexane)(maltolato)platinum(II) ([Pt(R,R-DACH)(ma)]+) (8) and the crystal structure of [Pt(R,R-DACH)(ma)]NO3. As well, we present the results of our cytotoxicity studies on these complexes and compare their behaviour with that of cisplatin and carboplatin.
Section snippets
Chemistry
Electrospray ionization-mass spectrometry (ESI-MS) spectra were recorded on a quadrupole ion trap Finnigan-MAT LCQ mass spectrometer equipped with electrospray ionisazation (ESI). Infra-red spectra were recorded on a BIO-RAD FT-IR spectrometer. NMR spectra were obtained on a Varian Unityplus 400 spectrometer at 400 MHz for 1H spectra and 85 MHz for 195Pt spectra. Sodium trimethylsilylpropanesulfonate was used as the standard for 1H NMR in D2O. 195Pt spectra were externally referenced to potassium
Chemistry
The complexes 7 and 8 were prepared by starting with the complexes Pt(en)I2 and Pt(R,R-DACH)I2, respectively, then removing the halogen as AgI to yield the corresponding diaqua complexes. The water ligands were then substituted by the maltolate anion, the formation of which was facilitated by the addition of about one equivalent of base along with maltol to the reaction mixture. Both complexes were isolated as nitrate salts. In the case of the DACH complex, sodium hydroxide was used as the
Conclusions
The information we have collected indicates that the synthesis of mixed ligand diamine maltolato platinum (II) complexes is relatively straightforward. The complexes 7 and 8 show good aqueous solubility and in the cell lines we have examined their cytotoxicities lie between cisplatin and carboplatin. As a result, the maltolate anion is an excellent candidate for incorporation as the leaving group in DNA targeted complexes such as the acridrine systems 1. The targeted acridine complexes 1 [3]
Acknowledgement
Support of this work by The National Health and Medical Research Council (W.D. Mc F., V.M., W.A.D.) is gratefully acknowledged.
References (19)
- et al.
J. Inorg. Biochem.
(2001) - et al.
J. Inorg. Biochem.
(2004) - et al.
J. Inorg. Biochem.
(1980) Inorg. Chim. Acta
(1987)- et al.
Polyhedron
(2000) - et al.
Anti-Cancer Drug Des.
(2001) - et al.
Biochemistry
(2000) - et al.
Chem. Rev.
(1999) - M. Muto, K. Matsunaga, S. Imamura, Hashimoto, Japanese Patent 01132596 A2 19890525 Heisei,...
Cited by (22)
A new copper(II) complex with 2-thenoyltrifluoroacetone and 2,2-bipyridine: Crystal structure, spectral properties and cytotoxic activity
2013, Journal of Molecular StructureSubstituted 9-aminoacridine-4-carboxamides tethered to platinum(II)diamine complexes: Chemistry, cytotoxicity and DNA sequence selectivity
2010, Journal of Inorganic BiochemistrySynthesis, characterization and biological activities of mononuclear Co(III) complexes as potential bioreductively activated prodrugs
2009, Journal of Inorganic BiochemistryThe DNA sequence selectivity of maltolato-containing cisplatin analogues in purified plasmid DNA and in intact human cells
2009, Journal of Inorganic BiochemistrySyntheses and structural studies of platinum(II) complexes of O-methylselenomethionine and related ligands
2006, Inorganica Chimica ActaIn vivo glioblastoma therapy using targeted liposomal cisplatin
2020, International Journal of Nanomedicine